Friday, January 16, 2015 4:31:00 PM
Stock Tickers
US:BNIKF (OTC) & BTEBY (ADR)
Australian: ASX:BLT
If you are new Benitec, this post has the majority of due diligence nuggets dug out for you by various board members. Welcome to Benitec Biopharma Ltd!
Benitec Biopharma is an Australian Biotech Company that is currently developing a platform method of treating diseases. Unlike traditional drugs, Benitec has developed a system of treatment utilizing viral vectors and a patented process known as ddRNAi, or DNA-directed RNA interference. What this means is that when their treatment is delivered, the modified virus takes the treatment into the target cell, and modifies that cell's DNA so that it effectively produces the therapy/cure itself. Benitec is currently utilizing this technology, in its first clinical trial, to target Hepatitic C. Other disease targets in development in-house are Hepatitis B, Non Small Cell Lung Cancer, Cancer Associated Pain, Age Related Macular Degeneration & Oculophayngeal Muscular Dystrophy.
Out-licenced Programs include HIV through Calimmune, Cancer Vaccine through Regen Biopharma, Retinitis Pigmentosa through Genable, Huntington's through uniQure, and Intractable Pain through Circuit Therapeutics.
To see Benitec’s in-house and out-licenced programs, click here:http://www.benitec.com/pipeline/in-house-programs
Presentations:
Benitec’s most recent presentation in San Francisco on January 16, 2014 can be viewed here: http://clients3.weblink.com.au/WebChartClientHeadlines/clients/canarynetworks/bc18lt12/01591444.pdf
ddRNAi:
Benitec announced the appointment of a Vice President of Manufacturing. That announcement can be seen here:http://blt.live.hqi.com.au/IRM/Company/ShowPage.aspx/PDFs/1483-10000000/MANUFACTURINGEXPERTAPPOINTED
Numerous articles detailing why Benitec has so much potential for revolutionizing how we treat diseases, and as a company itself, can be seen here:
http://seekingalpha.com/instablog/24166073-24166073/2773743-why-benitec-biopharma-bnikf-has-a-very-bright-future-ahead
It also details insights from the author on what very KEY points were made during theinvestor Briefing that took place this March as well.
UPDATE: November 9, 2014 – Another article by Pannobhaso on Seeking Alpha seeks to prognosticate the future of Benitec and ddRNAi here:http://seekingalpha.com/instablog/19837781-pannobhaso/3444735-ddrnai-center-of-excellence
Another article detailing more about Benitec’s patented ddRNAi tech can be read here:
http://seekingalpha.com/instablog/19837781-pannobhaso/2771933-ddrnai-is-in-the-eye-of-the-beholder?source=kizur_seekingalpha
Benitec as a company that has the potential to dramatically change the cost of healthcare can be read here:
http://seekingalpha.com/article/2083973-benitec-the-health-payers-dream-biotech
How Benitec’s method of ddRNAi is distinct from the typical RNAi treatment can be read here:
http://seekingalpha.com/article/2054223-benitec-an-undiscovered-biotechnology-with-a-twist
Short Hairpin RNA (short hairpin RNA “shRNA”) scientific videos can be seen here. These are more scientific in nature, and walkthrough the pathophysiology of how this functions:
Part 1
Part 2
Part 3
Part 4
Hepatitis C:
January 7, 2014 Update! - The third patient has been dosed today in Benitec’s Phase I/IIa clinical trial of TT-034 for hepatitis C.
The dosing regimen is as follows:
Cohort 1: (2 Patients) Dosed Sequentially (One after the other).
Patient 1: Dosed May 28, 2013
Patient 2: Dosed November 13, 2013
Cohort 2: (3 Patients) Dosed Sequentially (1) then Parallel (2). In other words, the first patient will be dosed, and then if deemed same, the next two patients will be dosed at the same time.
6 Week Observation period per subject and between cohorts before dose escalation
Patient 1: Dosed January 7, 2014.
Patient 2&3: Waiting to be dosed
Cohort 3:
Cohort 4:
Cohort 5:
For more information on dosing timlines, please see:http://www.irasia.com/listco/au/benitec/press/p140711.htm
November 9, 2014 Update: A November 3rd Interview regarding the TT-034 Clinical trial for Hepatitis C can be heard here: http://www.brrmedia.com/event/129281. In it, it details why certain people were excluded from the trial. This accounts for the delay in dosing the second patient in the first cohort next, and also talks about Benitec’s recent licensee Circuit Therapeutics. Dr. David Suhy, Benitec’s Senior Vice President of Research and Development, released an article this month detailing a comparison between Gilead Sciences recently approved Hepatitis C treatment, Harvoni, and TT-O34. That article can be read here:http://www.benitec.com/documents/1411_Harvoni_Why_Hep_C_Focus_is_a_Plus.pdf
Clinical Trials on ClinicalTrials.gov can be seen here:http://www.clinicaltrial.gov/ct2/show/NCT01899092?term=tt-034&rank=1
For a more scientific review regarding TT-034 as a recombinant adeno-associated virus serotype 8 (AAV8) agent used in the treatment of diseases (More specifically HCV in this case), can be seen here:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951910/
As of July 19, Benitec released a presentation for the Bioshare Summit in Australia. It details TT-034 and ddRNAi in comparison to Isys and Alnylam. This presentation can be seen here:
http://present.knowledgevision.com/player/mobile/version/2/0/index.html?config=http://present.knowledgevision.com/account/brr/player/BLT20140718/config/config.xml&kv_id=KnowledgeVisionEmbeddedContentdc93b1db7dfa4120a77642bb03edafa8&kv_presentationId=ODA2OTY%253D&kv_presentationVersion=1.0&kv_duration=907.778&kv_slideCount=29&kv_trackUrl=http%3A//track.presentation-cloud.net/&kv_licenseId=138&kv_subAccountId=-1
Or here:
http://www.brrmedia.com/event/124682/
Also, an Instablog on Seeking Alpha by Pannobhaso regarding TT-034’s intial positive results can be seen here: http://seekingalpha.com/author/pannobhaso/instablog
The VIDEO portion of their latest Spotlight Presentation can be watched here:http://www.finnewsnetwork.com.au/archives/finance_news_network76292.html
Tribetarna (Lung Cancer):
Benitec’s treatment for lung cancer is another avenue that is currently being worked on, and is detailed in a Youtube video from UNSW Australia… and can be watched here:
A Recent Announcement on January 8, 2015 detailed two peer-reviewed articles supporting Tribetarna’s expanded indications to pancreatic and renal cancer. That announcement can be seen here:http://blt.live.hqi.com.au/IRM/Company/ShowPage.aspx/PDFs/1499-10000000/RESEARCHSUPPORTSADDITIONALCANCERINDICATIONS
HIV and Callimune:
Here is a YouTube link regarding Tye Olson, one of the indivuals who is doing the Calimmune HIV trial using altered T-Cells with Benitec’s Tech. His trial is mentioned starting at around 6:20. This video was posted 04/14/2014.
A gene therapy presentation in regards to a cure for HIV can be seen here: www.isheid.com/presentations/mercredi/16-00/hutter/hutter.pdf
On June 25, 2014, a PR was released announcing that Calimmune has been given the green light to treat its second group in the HIV gene therapy trial. That announcement can be seen here:http://www.businesswire.com/news/home/20140625005962/en/Calimmune-Approved-Treat-Group-HIV-Stem-Cell#.U8HG3PldXzc
A recent post on Seeking Alpha with author Pannobhaso has listed Benitec’s ddRNAi technology in the fight against HIV in various ways. This article can be viewed here:http://seekingalpha.com/article/2418705-benitecs-ddrnai-targeting-fight-against-hiv
The 2015 Palm Springs Symposium on HIV Schedule of Events can be viewed here:http://cri.bio.uci.edu/events/2013-palm-springs-symposium-on-hivaids-hiv-infection-towards-a-cure/
As of 08/14/2014, An interesting patent application on HIV resistant stem cells and ddRNAi can be seen here: http://www.freepatentsonline.com/y2014/0227236.html
Huntington's Disease:
uniQure has licensed out Benitec's technology for Huntington's Disease.
Other Disease Areas to Note:
Alzheimer’s Public Forum – October 31, 2014
http://ausbiotech.org/updates/details.asp?cat=4&id=1164&returnToUrl=%2Fdefault%2Easp
Financials:
If you’re interested in viewing an Australian stock blog like Investorhub, you can view this one:http://www.topstocks.com.au/new_asx_stock_forum.php
as well as this one: http://hotcopper.com.au/search_do.asp?fid=1&symbol=382
As of 5-29-2014, Benitec has also announced it has chosen New York Bank of Mellon as its authorized U.S. representative and Depository Bank to establish an ADR (American Depositary Receipt) Facility. The announcement can be seen here:http://www.benitec.com/documents/140530USADRTOBEESTABLISHED.pdf
Other ddRNAi programs are potentially in the works for possibly ALS and can be read in a blog here: http://seekingalpha.com/author/pannobhaso/instablog
I will try to continually update this post when new information comes out. Again, Welcome!
For more information regarding the Australian releases on the ASX, please refer to this link: http://www.benitec.com/investor-centre/asx-announcements
Blane
Recent BNTC News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/29/2024 08:28:27 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/19/2024 08:59:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 09:18:32 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2024 02:22:02 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/29/2024 08:32:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:05:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 12:01:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:13:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:12:19 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 02/26/2024 02:06:56 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/23/2024 09:09:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:15:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 01:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 12:31:00 PM
- Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/17/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:03:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:00:49 PM
- Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/20/2023 08:31:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/20/2023 10:04:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:29:59 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM